Ignite Creation Date:
2025-12-24 @ 4:15 PM
Ignite Modification Date:
2026-02-03 @ 11:26 AM
Study NCT ID:
NCT03836066
Status:
COMPLETED
Last Update Posted:
2025-12-04
First Post:
2019-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
Sponsor:
Fundación GECP
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
GECP 18/03_TELMA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None